請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7742
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 王錦堂 | |
dc.contributor.author | Chih-Hua Kuo | en |
dc.contributor.author | 郭芷華 | zh_TW |
dc.date.accessioned | 2021-05-19T17:51:59Z | - |
dc.date.available | 2022-09-08 | |
dc.date.available | 2021-05-19T17:51:59Z | - |
dc.date.copyright | 2017-09-08 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-08-02 | |
dc.identifier.citation | 1. Zhou, H., et al., A novel treatment strategy in hepatocellular carcinoma by down-regulation of histone deacetylase 1 expression using a shRNA lentiviral system. Int J Clin Exp Med, 2015. 8(10): p. 17721-17729.
2. Ingle, P.V., et al., Development and novel therapeutics in hepatocellular carcinoma: a review. Ther Clin Risk Manag, 2016. 12: p. 445-55. 3. Yuen, M.F., et al., Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol, 2009. 24(3): p. 346-53. 4. Kew, M., Hepatocellular carcinoma: epidemiology and risk factors. Journal of Hepatocellular Carcinoma, 2014: p. 115. 5. Venook, A.P., et al., The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective. The Oncologist, 2010. 15(Supplement 4): p. 5-13. 6. Sanyal, A.J., S.K. Yoon, and R. Lencioni, The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist, 2010. 15 Suppl 4: p. 14-22. 7. Kew, M.C., H.A. Dos Santos, and S. Sherlock, Diagnosis of Primary Cancer of the Liver. British Medical Journal, 1971. 4: p. 408-411. 8. El-Serag, H.B., M.D., and M.P.H., Hepatocellular Carcinoma. N Engl J Med, 2011. 365: p. 1118-1127. 9. Chhaniwal, N., et al., Hepatocellular Carcinoma: Review of Current Treatment with a Focus on Transarterial Chemoembolization and Radiofrequency Ablation. Open Journal of Radiology, 2015. 05(01): p. 50-58. 10. Luedde, T. and R.F. Schwabe, NF-kappaB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 2011. 8(2): p. 108-18. 11. Ye, H., et al., Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice. Oncogene, 2014. 33(43): p. 5133-8. 12. European Association For The Study Of The Liver and European Organisation For Research Treatment Of Cancer, EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol, 2012. 56(4): p. 908-43. 13. Robbins, P.D. and S.C. Ghivizzani, Viral Vectors for Gene Therapy. Pharmacol Ther, 1998. 80(1): p. 35-47. 14. Otto, W.M. and R. Mohamed Al, Viral Vectors for Gene Therapy. 2011. 15. Escors, D., et al., Development of Retroviral and Lentiviral Vectors. 2012: p. 11-28. 16. Luigi, N., Lentiviruses as gene transfer agents for delivery to non-dividing. Current Opinion in Biotechnology, 1998. 9: p. 457-463. 17. Cronin, J., X.-Y. Zhang, and J. Reiser, Altering the Tropism of Lentiviral Vectors through Pseudotyping. Curr Gene Ther, 2005. 5(4): p. 387-398. 18. Tiscornia, G., O. Singer, and I.M. Verma, Production and purification of lentiviral vectors. Nature Protocols, 2006. 1(1): p. 241-245. 19. Matrai, J., M.K. Chuah, and T. VandenDriessche, Recent advances in lentiviral vector development and applications. Mol Ther, 2010. 18(3): p. 477-90. 20. Dropulic, B., Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research. Hum Gene Ther, 2011. 22(6): p. 649-57. 21. Goyvaerts, C., et al., Targeted Lentiviral Vectors: Current Applications and Future Potential. 2013. 22. Kochan, G., et al., Clinical Grade Lentiviral Vectors. 2012: p. 69-85. 23. Lingor, P., Regulation of Cell Death and Survival by RNA Interference – The Roles of miRNA and siRNA. 2010: p. 95-117. 24. Luo, B., et al., Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A, 2008. 105(51): p. 20380-5. 25. Marcotte, R., et al., Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov, 2012. 2(2): p. 172-89. 26. Ngo, V.N., et al., A loss-of-function RNA interference screen for molecular targets in cancer. Nature, 2006. 441(7089): p. 106-10. 27. Pilotte, L., et al., Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A, 2012. 109(7): p. 2497-502. 28. Thackray, S.J., C.G. Mowat, and S.K. Chapman, Exploring the mechanism of tryptophan 2,3-dioxygenase. Biochem Soc Trans, 2008. 36(Pt 6): p. 1120-3. 29. Moon, Y.W., et al., Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer, 2015. 3: p. 51. 30. Pantouris, G., J. Loudon-Griffiths, and C.G. Mowat, Insights into the mechanism of inhibition of tryptophan 2,3-dioxygenase by isatin derivatives. J Enzyme Inhib Med Chem, 2016: p. 1-9. 31. Platten, M., et al., Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors. Frontiers in Immunology, 2015. 5(673). 32. Hjortso, M.D., et al., Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer. Oncoimmunology, 2015. 4(1): p. e968480. 33. Dolusic, E., et al., Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. J Med Chem, 2011. 54(15): p. 5320-34. 34. Opitz, C.A., et al., An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature, 2011. 478(7368): p. 197-203. 35. Wang, Y., et al., RPS24 knockdown inhibits colorectal cancer cell migration and proliferation in vitro. Gene, 2015. 571(2): p. 286-291. 36. Feng, D., et al., Inhibiting the Expression of DNA Replication-Initiation Proteins Induces Apoptosis in Human Cancer Cells. Cancer Res, 2003. 63(21): p. 7356-64. 37. Yan, P., et al., Decreasing CNPY2 Expression Diminishes Colorectal Tumor Growth and Development through Activation of p53 Pathway. Am J Pathol, 2016. 186(4): p. 1015-24. 38. Lin, Y.N., et al., Expression of DIAPH1 is up-regulated in colorectal cancer and its down-regulation strongly reduces the metastatic capacity of colon carcinoma cells. Int J Cancer, 2014. 134(7): p. 1571-82. 39. Hu, B., et al., Nucleostemin/GNL3 promotes nucleolar polyubiquitylation of p27kip1 to drive hepatocellular carcinoma progression. Cancer Lett, 2017. 388: p. 220-229. 40. Chen, W., et al., Emerging role of microRNA-27a in human malignant glioma cell survival via targeting of prohibitin. Mol Med Rep, 2015. 12(1): p. 1515-23. 41. Xu, X.Y., et al., Down-regulated MAC30 expression inhibits proliferation and mobility of human gastric cancer cells. Cell Physiol Biochem, 2014. 33(5): p. 1359-68. 42. Lee, C., et al., Overexpressed tryptophanyl-tRNA synthetase, an angiostatic protein, enhances oral cancer cell invasiveness. oncotarget, 2015. 6(26): p. 21979-92. 43. Vaisitti, T., et al., The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. Leukemia, 2015. 29(2): p. 356-68. 44. Li, W., et al., A novel human TINP1 gene promotes cell proliferation through inhibition of p53 and p21 expression. Oncol Rep, 2013. 30(4): p. 1848-52. 45. Mouillesseaux, K. and J.N. Chen, Mutation in utp15 disrupts vascular patterning in a p53-dependent manner in zebrafish embryos. PLoS One, 2011. 6(9): p. e25013. 46. Lykke-Andersen, K., et al., Disruption of the COP9 Signalosome Csn2 Subunit in Mice Causes Deficient Cell Proliferation, Accumulation of p53 and Cyclin E, and Early Embryonic Death. Molecular and Cellular Biology, 2003. 23(19): p. 6790-6797. 47. Kuo, P.C., et al., Breast cancer amplified sequence 2, a novel negative regulator of the p53 tumor suppressor. Cancer Res, 2009. 69(23): p. 8877-85. 48. Hua, L., et al., Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma. Pathol Res Pract, 2017. 213(6): p. 688-697. 49. Kispert, S.E., J.O. Marentette, and J. McHowat, Enhanced breast cancer cell adherence to the lung endothelium via PAF acetylhydrolase inhibition: a potential mechanism for enhanced metastasis in smokers. AJP: Cell Physiology, 2014. 307(10): p. C951-C956. 50. Shi, J., et al., Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells. Oncogene, 2006. 25(35): p. 4923-36. 51. Patel, R.D., et al., The Aryl Hydrocarbon Receptor Directly Regulates Expression of the Potent Mitogen Epiregulin. Toxicological Science, 2006. 89(1): p. 75-82. 52. Wang, C., et al., Aryl hydrocarbon receptor activation and overexpression upregulated fibroblast growth factor-9 in human lung adenocarcinomas. 2009. 125(4): p. 807-815. 53. Murray, I.A., A.D. Patterson, and G.H. Perdew, Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer, 2014. 14(12): p. 801-14. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7742 | - |
dc.description.abstract | 肝癌為全球盛行癌症第五名,對於其治療或是基因檢測還沒有很好的指標,所以想要利用human pooled shRNA lentiviruses library以negative selection的方式尋找肝癌生長的特異基因。將human pooled shRNA lentiviruses library pool 2分別感染四種不同的癌症細胞株,原本包含了9984個shRNA,結果發現人類肝細胞癌細胞株Huh7、人類肺腺癌細胞株A549、人類子宮頸癌細胞株HeLa、人類胃癌細胞株SCM1共同沒有比對到的shRNA有423個,涵蓋307個基因,而只有人類肝細胞癌細胞株Huh7沒有比對到的shRNA則有334個,涵蓋303個基因。有研究顯示抑制色胺酸雙加氧酶(tryptophan 2,3-dioxygenase, TDO2)可使T細胞重新獲得對抗腫瘤的能力,所以想要探討是否可以藉由shRNA抑制TDO2基因表現來抑制肝腫瘤的生長。利用定量及時聚合酶連鎖反應,發現shRNA clone ID 874、33分別抑制人類肝癌細胞株Huh7、小鼠肝癌細胞株Hep55.1c和小鼠肝臟上皮細胞株BNL1.MEA的TDO2基因表現的效果最好。以西方墨點法偵測被shRNA clone ID 33慢病毒感染後的Hep55.1c細胞株、被scramble shRNA慢病毒感染後的Hep55.1c細胞株以及未被感染的Hep55.1c細胞株之色胺酸雙加氧酶表現量,因為陽性控制組沒有明顯的band,所以無法確定細胞色胺酸雙加氧酶表現量。以MTT試驗測定細胞增生,在第五天時,未被感染的Hep55.1c細胞株之粒線體活性比被shRNA clone ID 33慢病毒感染後的Hep55.1c細胞株和被scramble shRNA慢病毒感染後的Hep55.1c細胞株數值高,且有顯著差異,表示未被感染的Hep55.1c細胞株生長速度較快。皮下注射動物實驗方面,在C57BL/6小鼠打入被shRNA clone ID 33慢病毒感染後的細胞形成的腫瘤比被scramble shRNA慢病毒感染後的細胞形成的腫瘤小,且在第十五天有顯著差異,但在BALB/C小鼠則沒有顯著差異。肝臟注射動物實驗方面,不管是在C57BL/6或BALB/C小鼠,打入被shRNA clone ID 33慢病毒感染後的細胞形成的腫瘤大小與被scramble shRNA慢病毒感染後的細胞形成的腫瘤大小都沒有顯著差異。 | zh_TW |
dc.description.abstract | Hepatocellular carcinoma is the fifth most prevalent cancer worldwide. So far, there are no good indicators for its treatment or early diagnosis. Therefore, we wanted to use human pooled shRNA lentiviruses library to identify genes that are specific to hepatocellular carcinoma growth by negative selection. Four different types of cancer cell lines were infected by human pooled shRNA lentiviruses library pool 2 which had 9984 shRNA. There were 423 shRNA including 307 genes which were not aligned in Huh7, A549, HeLa and SCM1 cells. Additionally, there were 334 shRNA including 303 genes which were not aligned only in Huh7 cell. Previous studies showed that inhibiting tryptophan 2,3-dioxygenase (TDO2) allowed T cell to regain the ability to attack tumor. Thus, we wanted to investigate whether using shRNA to inhibit TDO2 gene expression can repress the growth of hepatocellular carcinoma. By real time qPCR, we found that shRNA clone ID 874 and 33 inhibited the TDO2 gene expression levels of Huh7, Hep55.1c and BNL1.MEA cells most efficiently respectively. The protein levels of tryptophan 2,3-dioxygenase of scramble shRNA treated Hep55.1c, shRNA clone ID 33 treated Hep55.1c and non-treated Hep55.1c cells were detected by western blot. We couldn’t confirm the protein levels of tryptophan 2,3-dioxygenase of these cells because there wasn’t a distinct band in positive control. Using MTT assay to detect the proliferation rate of non-treated Hep55.1c, scramble shRNA treated Hep55.1c and shRNA clone ID 33 treated Hep55.1c cells. We found that the activity of mitochondria in non-treated Hep55.1c cells was significantly higher than scramble shRNA treated Hep55.1c and shRNA clone ID 33 treated Hep55.1c cells at day 5 indicating that the proliferation rate of non-treated Hep55.1c cells was faster. In subcutaneous injection, the size of tumors derived from shRNA clone ID 33 treated cells was significantly smaller than those from scramble shRNA treated cells at day 15 in C57BL/6 but not in BALB/C mice. However, in liver injection, there was no significant difference between the size of tumors derived from shRNA clone ID 33 treated cells and those from scramble shRNA treated cells in C57BL/6 or BALB/C mice. | en |
dc.description.provenance | Made available in DSpace on 2021-05-19T17:51:59Z (GMT). No. of bitstreams: 1 ntu-106-R04445105-1.pdf: 1824948 bytes, checksum: bc80772b2a310550486ec2946186e4b0 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 口試委員審定書 i
誌謝 ii 中文摘要 iii Abstract iv 目錄 vi 圖目錄 viii 表目錄 ix 第一章 緒論 1 1.1 肝癌簡介 1 1.2 基因治療載體 1 1.3 小髮夾核糖核酸(Small hairpin RNA, shRNA)的作用機制 3 1.4 Pooled RNAi library 3 1.5 色胺酸雙加氧酶(Tryptophan 2,3-dioxygenase) 3 1.6 研究動機 5 第二章 材料與方法 6 2.1 材料 6 2.1.1 細胞株 6 2.1.2 藥品 6 2.1.3 Pool RNAi library及TDO2 targeted shRNA 6 2.1.4 引子(Primers) 6 2.2 利用pooled shRNA library尋找肝癌生長的特異基因 7 2.2.1 以110K human pooled shRNA lentiviruses library pool 2感染細胞 7 2.2.2 抽取細胞基因體DNA(Genomic DNA) 7 2.2.3 以聚合酶連鎖反應(Polymerase chain reaction)放大shRNA序列 8 2.2.4 以限制酶切除shRNA loop結構 (Restriction enzyme digestion) 9 2.2.5 Klenow 9 2.2.6 次世代定序(Next Generation Sequencing) 10 2.3 以shRNA抑制TDO2基因 10 2.3.1 以包裹著TDO2 targeted shRNA的慢病毒感染細胞 10 2.3.2 抽取細胞total RNA 11 2.3.3 反轉錄定量即時聚合酶連鎖反應(Reverse transcription- quantitative real time polymerase chain reaction , RT-qPCR) 11 2.3.4 萃取細胞蛋白質 13 2.3.5 聚丙烯醯胺膠體電泳(Sodium dodecyl sulfate - Polyacrylamide gel electrophoresis,SDS-PAGE)與西方墨點法(Western blot) 14 2.3.6 MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)試驗 17 2.3.7 小鼠動物實驗 17 第三章 結果 18 3.1 以次世代定序分析第二代樣本 18 3.2 利用RT-qPCR測定針對TDO2基因之shRNA的抑制效果 19 3.2.1 以慢病毒感染人類肝細胞癌細胞株Huh7,並測定TDO2 mRNA的表現量 19 3.2.2 以慢病毒感染小鼠肝癌細胞株Hep55.1c,並測定Tdo2 mRNA的表現量 19 3.2.3 以慢病毒感染小鼠肝臟上皮細胞株BNL1.MEA,並測定Tdo2 mRNA的表現量 19 3.2.4 shRNA與TDO2基因序列分析 20 3.2.5 以西方墨點法偵測細胞色胺酸雙加氧酶(Tryptophan dioxygenase)的表現量 20 3.2.6 以MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)試驗測定細胞增生 20 3.2.7 小鼠動物實驗 21 第四章 總結與討論 23 參考文獻 45 附錄 48 | |
dc.language.iso | zh-TW | |
dc.title | 利用Pooled RNAi Library尋找肝癌生長的特異基因 | zh_TW |
dc.title | Identify Genes that are Specific to Hepatocellular Carcinoma Growth by Using Pooled RNAi Library | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蔡丰喬,董馨蓮 | |
dc.subject.keyword | 肝細胞癌,基因組篩選,色胺酸雙加氧?,小髮夾核醣核酸,慢病毒, | zh_TW |
dc.subject.keyword | Hepatocellular carcinoma,Genome-wide screening,Tryptophan 2,3-dioxygenase,Small hairpin RNA,Lentivirus, | en |
dc.relation.page | 62 | |
dc.identifier.doi | 10.6342/NTU201702453 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2017-08-02 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf | 1.78 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。